Peter Lynch's long-term investment approach seeks companies with steady, sustainable earnings growth and a reasonable valuation, a style sometimes described as growth at a reasonable price. UNITED THERAPEUTICS CORP (NASDAQ:UTHR) is a biotechnology company that develops therapies for chronic and life-threatening conditions, and it currently ticks most of the boxes that a Lynch-style screen looks for. The company combines a strong growth record with an inexpensive valuation and an exceptionally clean balance sheet, making it a candidate for investors who want to own growing businesses without overpaying for them.
Why United Therapeutics fits the Lynch playbook
Lynch favored companies that could grow earnings per share at a pace between 15% and 30% annually, reasoning that faster growth is often unsustainable. United Therapeutics has delivered EPS growth of roughly 19.2% per year over the past five years, placing it squarely in that target zone. Crucially, the stock also trades at a PEG ratio near 0.95, based on historical earnings growth, which means the market is not asking investors to pay a premium for that growth.
The rest of the quantitative checklist is equally supportive. The company has no outstanding debt, giving it a debt-to-equity ratio of 0.0, far below the 0.6 threshold Lynch preferred. Its current ratio stands at 5.73, indicating ample liquidity to cover short-term obligations. Return on equity comes in at 20.48%, well above the 15% level Lynch used to identify profitable, well-managed businesses.
The key Peter Lynch criteria and United Therapeutics' values:
- EPS growth (5-year): 19.23%, within the 15% to 30% range
- PEG ratio: 0.95, below the 1.0 limit
- Debt/Equity: 0.0, versus the 0.6 maximum
- Current ratio: 5.73, versus the 1.0 minimum
- ROE: 20.48%, versus the 15% requirement
A fundamentally sound profile
The broader fundamental picture reinforces the screen's findings. United Therapeutics carries a fundamental rating of 7 out of 10, with particularly strong scores for profitability and financial health. Its profit margin is 41.56%, while operating margin is 44.49%, and the company has generated positive operating cash flow in each of the past five years. The return on invested capital is also solid at 16.50%, meaning management is putting capital to work efficiently.
That combination of profitability and balance sheet strength is exactly what Lynch looked for before buying and holding for the long term. A company with low debt and high margins has more room to fund its own growth or return capital to shareholders through buybacks. The screen also notes that United Therapeutics has fewer shares outstanding than it did one year and five years ago, a sign of ongoing share repurchases, another trait Lynch appreciated.
Investors who want to review the full fundamental breakdown can use this fundamental analysis page.
Risks to keep in mind
No screen can eliminate risk, and United Therapeutics operates in a space where clinical trial outcomes, regulatory decisions, and product competition can move the stock sharply. The company's growth is also expected to slow from its historical pace. Analysts currently forecast EPS growth of about 13.54% per year going forward, which is still healthy but below the 15% lower bound that Lynch's screen favors. If that estimate is revised lower, the stock may no longer qualify under the same criteria.
Additionally, while the valuation looks reasonable relative to the industry, the stock's price-to-earnings ratio of 18.31 is not ultra cheap on an absolute basis. Lynch's strategy always required further homework beyond the screen, including an understanding of the competitive moat and the durability of the growth drivers.
Supporting screens reinforce the quality story
Beyond the Lynch-style criteria, UTHR also passes quality-focused screens. The high-ROIC screen lists the stock for its strong return on invested capital, a sign that management is allocating capital efficiently. The high free cash flow screen similarly includes UTHR, reflecting strong cash generation and the flexibility to keep returning capital to shareholders.
The bottom line for long-term investors
United Therapeutics presents a useful example of how Lynch's principles can identify established growers trading at sensible prices. Its earnings growth is strong without being explosive, its valuation is supported by that growth, and its financial health is among the best in its industry. For investors building a diversified portfolio of companies they can hold for years, that combination is worth serious consideration. More stocks that currently match this methodology can be found in the latest Peter Lynch screen.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
United Therapeutics (NASDAQ:UTHR): A Peter Lynch-Style GARP Play
Peter Lynch's long-term investment approach seeks companies with steady, sustainable earnings growth and a reasonable valuation, a style sometimes described as growth at a reasonable price. UNITED THERAPEUTICS CORP (NASDAQ:UTHR) is a biotechnology company that develops therapies for chronic and life-threatening conditions, and it currently ticks most of the boxes that a Lynch-style screen looks for. The company combines a strong growth record with an inexpensive valuation and an exceptionally clean balance sheet, making it a candidate for investors who want to own growing businesses without overpaying for them.
Why United Therapeutics fits the Lynch playbook
Lynch favored companies that could grow earnings per share at a pace between 15% and 30% annually, reasoning that faster growth is often unsustainable. United Therapeutics has delivered EPS growth of roughly 19.2% per year over the past five years, placing it squarely in that target zone. Crucially, the stock also trades at a PEG ratio near 0.95, based on historical earnings growth, which means the market is not asking investors to pay a premium for that growth.
The rest of the quantitative checklist is equally supportive. The company has no outstanding debt, giving it a debt-to-equity ratio of 0.0, far below the 0.6 threshold Lynch preferred. Its current ratio stands at 5.73, indicating ample liquidity to cover short-term obligations. Return on equity comes in at 20.48%, well above the 15% level Lynch used to identify profitable, well-managed businesses.
The key Peter Lynch criteria and United Therapeutics' values:
A fundamentally sound profile
The broader fundamental picture reinforces the screen's findings. United Therapeutics carries a fundamental rating of 7 out of 10, with particularly strong scores for profitability and financial health. Its profit margin is 41.56%, while operating margin is 44.49%, and the company has generated positive operating cash flow in each of the past five years. The return on invested capital is also solid at 16.50%, meaning management is putting capital to work efficiently.
That combination of profitability and balance sheet strength is exactly what Lynch looked for before buying and holding for the long term. A company with low debt and high margins has more room to fund its own growth or return capital to shareholders through buybacks. The screen also notes that United Therapeutics has fewer shares outstanding than it did one year and five years ago, a sign of ongoing share repurchases, another trait Lynch appreciated.
Investors who want to review the full fundamental breakdown can use this fundamental analysis page.
Risks to keep in mind
No screen can eliminate risk, and United Therapeutics operates in a space where clinical trial outcomes, regulatory decisions, and product competition can move the stock sharply. The company's growth is also expected to slow from its historical pace. Analysts currently forecast EPS growth of about 13.54% per year going forward, which is still healthy but below the 15% lower bound that Lynch's screen favors. If that estimate is revised lower, the stock may no longer qualify under the same criteria.
Additionally, while the valuation looks reasonable relative to the industry, the stock's price-to-earnings ratio of 18.31 is not ultra cheap on an absolute basis. Lynch's strategy always required further homework beyond the screen, including an understanding of the competitive moat and the durability of the growth drivers.
Supporting screens reinforce the quality story
Beyond the Lynch-style criteria, UTHR also passes quality-focused screens. The high-ROIC screen lists the stock for its strong return on invested capital, a sign that management is allocating capital efficiently. The high free cash flow screen similarly includes UTHR, reflecting strong cash generation and the flexibility to keep returning capital to shareholders.
The bottom line for long-term investors
United Therapeutics presents a useful example of how Lynch's principles can identify established growers trading at sensible prices. Its earnings growth is strong without being explosive, its valuation is supported by that growth, and its financial health is among the best in its industry. For investors building a diversified portfolio of companies they can hold for years, that combination is worth serious consideration. More stocks that currently match this methodology can be found in the latest Peter Lynch screen.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »